Board of Directors
Thomas Paul Koestler, Member of the Board
Thomas Paul Koestler is an executive with Vatera Holdings LLC, US. From 2003 to 2009 he was executive vice president and from 2006 president of Schering-Plough Research Institute, US. Before joining Schering-Plough Research Institute he was senior vice president & global head of Regulatory Affairs of Pharmacia Corporation, US, from 2001. From 1996 to 2001 Dr Koestler was vice president, later senior vice president in Novartis Pharmaceuticals within Regulatory Affairs. From 1982 to 1996 Dr Koestler held various management positions within Regulatory Affairs and Clinical Safety in Sandoz Pharmaceutical Corporation, Johnson & Johnson, Bristol-Myers Squibb, and Smith Kline French Labs, all in the US.
Dr Koestler is chairman of the board of Melinta Therapeutics Inc. and a member of the boards of Momenta Pharmaceuticals Inc., ImmusanT Inc., Arisaph Pharmaceuticals Inc., and Edgemont Pharmaceuticals LLC, all in the US.
Dr Koestler has a Bachelor of Science, Biology, from Daemen College from 1975 and a PhD in Medicine & Pathology from the Roswell Park Memorial Institute from 1982, both in the US.
Dr Koestler was first elected to the Board of Novo Nordisk A/S in March 2011 and has most recently been re-elected in March 2014. His term as a board member expires in March 2015.
In March 2014, the Board of Directors of Novo Nordisk A/S assessed that Dr Koestler is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by NASDAQ Copenhagen (2013).
In January 2014, the Board of Directors assessed that the special competences possessed by Dr Koestler is his extensive R&D knowledge, both generally and within the field of regulatory affairs. Dr Koestler also possesses significant know-how about the pharmaceutical industry in general and how large international corporations operate. As a US citizen Dr Koestler has additional knowledge of the US market.
Dr Koestler is a male US national, born June 1951.